Our study included a larger number of IBD patients (n = 40) and extended the analysis of IDO1 expression and activity to further immunotherapy (namely, the anti-α4β7 integrinVDZ and the anti-IL12/23 UST). This evidence concerns the gene IDO1 and inflammatory bowel disease.